You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

Displaying 1 - 10 of 8034 results
  1. Care4AD: A Comprehensive Care Coordination and Management Platform for Alzheimer Disease and Related Dementias

    SBC: BioSensics LLC            Topic: NIA

    ABSTRACT Care for persons with dementia requires constant and effective management and coordination of delivery of care between caregivers and family members. A robust, technology-driven solution for care management and coordination could significantly reduce the burden of caregiving and improve quality of life for patients with Alzheimer’s disease (AD). A few attempts have been made to use tech ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a novel broad-spectrum inhibitor of non-polio enteroviruses associated with acute flaccid myelitis

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Development of a novel broad-spectrum inhibitor of non-polio enteroviruses associated with acute flaccid myelitis Summary: Despite the eradication of poliovirus in the US and Europe more than 20 years ago, the number of cases of childhood paralysis associated with acute flaccid myelitis (AFM) has been increasing since 2014. This surge correlates with a rise in the number of diagnosed infections of ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Algorithm for the Real-Time Detection of Absence Seizures from Oculometric Data

    SBC: Eysz, Inc.            Topic: NINDS

    Abstract Eysz, Inc. is developing an algorithm and software solutions to reliably and affordably detect seizures in an ambulatory setting using existing smart glass technologies. In a proof-of-concept study, Eysz was able to detect andgt;75% of all absence seizures longer than 10 s in duration using only oculometric variables (e.g., pupil size, pupil location, eccentricity, blink frequency) detect ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a topical fixed-dose combination drug for peripheral neuropathic pain.

    SBC: WinSanTor, Inc.            Topic: NINDS

    PROJECT SUMMARY An estimated 30 million people in the United States suffer from some form of peripheral neuropathy, a condition that develops as a result of damage to the peripheral nervous system. The top two major causes of peripheral neuropathy in the US are diabetes mellitus (both T1DM and T2DM) and chemotherapeutic agents. Currently, there are no FDA-approved treatments to prevent or reverse ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a non-opioid chemogenetic therapy for chronic neuropathic pain

    SBC: CODA Biotherapeutics, Inc.            Topic: NINDS

    Project Summary/Abstract Current pharmacological and surgical treatments frequently fail to produce effective and/or durable neuropathic pain relief and are associated with severe side- or off-target effects. CODA Biotherapeutics is developing a powerful, targeted approach to treating chronic neuropathic pain that overcomes many conventional limitations. Our chemogenetic strategy is unique in that ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Care Improving Cognition for ADolescents on the Autism Spectrum (CICADAS)

    SBC: Posit Science Corporation            Topic: 104

    PROJECT SUMMARY The goal of the current project is to elaborate upon, reconstruct and advance to pivotal trial readiness CICADAS (Care Improving Cognition for ADolescents on the Autism Spectrum)—a clinician-assisted, closed-loop technology, mobile application for adolescents with Autism Spectrum Disorder (ASD). Via ten mobile assessments CICADAS will capture data on sensory processing abnormalit ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Abstract Pseudomonas aeruginosa (PA) is the bacterium most frequently isolated from the respiratory tract of ICU pa- tients in the US and is a major cause of pneumonia in intubated patients. Furthermore, infection with PA gener- ally has a poor prognosis, with an estimated 40-69% of PA ventilator-associated pneumonia (VAP) cases re- sulting in mortality, and more than 30% of survivors suffer recur ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. MucoCept-CVN, a genetically enhanced vaginal Lactobacillus strain for the prevention of HIV acquisition in women: Finalization of formulation for the first-in-human clinical trial

    SBC: OSEL, INC.            Topic: NIAID

    Project Summary Half of new HIV infections occur in women as a result of unprotected vaginal intercourse with an infected partner. The cervicovaginal mucosa is the primary portal of entry for HIV in women. Women often cannot protect themselves due to imbalances in sexual relationships. The long-term goal of this project is to develop a safe and effective product to prevent HIV acquisition in women ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. An antisense oligonucleotide therapy for KCNT1 based epileptic encephalopathies

    SBC: Q-State Biosciences, Inc.            Topic: 106

    Project Summary: Malignant Migrating Partial Seizures of Infancy (MMPSI) is a severe epileptic encephalopathy (EE) resulting in intractable seizures and severe developmental delays. It manifests early in childhood and can have devastating impacts on affected individuals and their families. Mutations in a gene called KCNT1 have been associated with MMPSI. KCNT1 encodes an ion channel, highly expres ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Salmonella typhimurium-based Bacteriotherapy for Orphan Benign Tumors: Neurofibromatosis Type II (NF2)

    SBC: Mulberry Biotherapeutics, Inc.            Topic: NINDS

    Neurofibromatosis type 2 (NF2) is a rare genetic disorder that affects about 1 in 25,000 individuals globally. While usually benign, these tumors result in severe morbidity and mortality in affected individuals. Almost all NF2 patients lose their hearing, and many lose the ability to walk and even to see. NF2 patients’ average age at death is 36 years, many of whom die in adolescence or early ad ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government